UBS Group Forecasts Strong Price Appreciation for Elanco Animal Health (NYSE:ELAN) Stock

Elanco Animal Health (NYSE:ELAN) had its price target increased by investment analysts at UBS Group from $31.00 to $33.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. UBS Group’s target price indicates a potential upside of 34.78% from the stock’s previous close.

ELAN has been the topic of a number of other research reports. TD Cowen raised their price objective on Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a report on Thursday, June 18th. Weiss Ratings upgraded shares of Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, July 31st. Citigroup raised their price target on shares of Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Piper Sandler reaffirmed an “overweight” rating on shares of Elanco Animal Health in a research note on Monday, June 29th. Finally, Morgan Stanley increased their price objective on shares of Elanco Animal Health from $23.00 to $26.00 and gave the company an “equal weight” rating in a report on Wednesday, July 22nd. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Elanco Animal Health currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.09.

Elanco Animal Health Stock Performance

Shares of ELAN stock traded down $1.74 during trading hours on Thursday, hitting $24.48. The company’s stock had a trading volume of 12,428,110 shares, compared to its average volume of 5,442,954. The company has a 50 day moving average of $24.73 and a 200 day moving average of $24.10. The stock has a market cap of $12.23 billion, a PE ratio of -48.89, a price-to-earnings-growth ratio of 1.67 and a beta of 1.67. The company has a current ratio of 2.16, a quick ratio of 1.12 and a debt-to-equity ratio of 0.60. Elanco Animal Health has a 12-month low of $15.50 and a 12-month high of $27.98.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.07. The business had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.31 billion. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. The company’s revenue was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.26 earnings per share. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. On average, sell-side analysts forecast that Elanco Animal Health will post 1.11 EPS for the current fiscal year.

Insider Buying and Selling at Elanco Animal Health

In other news, CEO Jeffrey N. Simmons bought 4,971 shares of the stock in a transaction that occurred on Friday, May 15th. The stock was purchased at an average price of $20.09 per share, for a total transaction of $99,867.39. Following the completion of the purchase, the chief executive officer owned 171,971 shares in the company, valued at approximately $3,454,897.39. This trade represents a 2.98% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Rajeev A. Modi purchased 4,911 shares of the stock in a transaction that occurred on Friday, May 15th. The stock was acquired at an average cost of $20.35 per share, with a total value of $99,938.85. Following the completion of the acquisition, the insider directly owned 160,812 shares of the company’s stock, valued at $3,272,524.20. This represents a 3.15% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 1.14% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Elanco Animal Health

Large investors have recently bought and sold shares of the stock. NewEdge Advisors LLC grew its holdings in shares of Elanco Animal Health by 133.7% during the fourth quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock worth $25,000 after purchasing an additional 627 shares during the last quarter. Root Financial Partners LLC lifted its holdings in shares of Elanco Animal Health by 50.7% in the 4th quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock valued at $40,000 after purchasing an additional 592 shares during the last quarter. Uniplan Investment Counsel Inc. acquired a new stake in shares of Elanco Animal Health in the 4th quarter valued at about $41,000. Torren Management LLC acquired a new stake in shares of Elanco Animal Health in the 4th quarter valued at about $46,000. Finally, Bessemer Group Inc. grew its stake in Elanco Animal Health by 33.2% during the 1st quarter. Bessemer Group Inc. now owns 2,105 shares of the company’s stock worth $50,000 after buying an additional 525 shares during the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health News Summary

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: Elanco reported second-quarter adjusted EPS of $0.34, above the $0.27 consensus estimate, while revenue rose 10.2% year over year to $1.368 billion, exceeding expectations of $1.31 billion. Elanco Animal Health Reports Second Quarter 2026 Results
• Positive Sentiment: Management raised full-year 2026 adjusted EPS guidance to $1.10-$1.16 from its prior outlook, increased revenue guidance to $5.09-$5.14 billion, lifted adjusted EBITDA guidance to $1.01-$1.035 billion, and raised its innovation-revenue target to $1.25 billion. Zenrelia reportedly reached blockbuster status. Elanco posts Q2 beat as Zenrelia hits blockbuster status
• Positive Sentiment: KeyCorp raised its price target for ELAN to $30 from $29 and maintained an “overweight” rating, indicating continued analyst confidence in the company’s growth outlook. KeyCorp price target update
• Neutral Sentiment: Third-quarter guidance calls for adjusted EPS of $0.19-$0.22 and revenue of approximately $1.2 billion, broadly in line with consensus. That limited near-term upside may be contributing to the weaker stock reaction.
• Negative Sentiment: Although adjusted results were strong, reported net income was $54 million and reported EPS was $0.11. Elanco also remains leveraged at 3.1 times adjusted EBITDA, so investors may remain cautious about debt reduction and the company’s negative GAAP net margin.
• Neutral Sentiment: A Zacks comparison with Addus HomeCare focuses on relative valuation rather than a new company-specific catalyst, potentially prompting investors to reassess whether ELAN’s recent gains adequately reflect its improved outlook. ADUS vs. ELAN: Which Stock Is the Better Value Option?

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.